Inhalers play a critical role in the management of chronic obstructive pulmonary disease (COPD). However, despite their proven efficacy, cost-related nonadherence and improper use results in skipped doses and sub-optimal treatment for patients. These barriers are particularly pronounced among Black patients, who are disproportionately affected by COPD.

Humana implemented a program to reduce COPD medication costs and provide medication support services, including education on proper inhaler use, for Medicare Advantage beneficiaries living with COPD.

A recent JAMA Internal Medicine study evaluated the program’s impact. The study was led by recent PhD student, Sumit Agarwal, and co-authored by Department of Health Care Policy Professors Michael E. Chernew, PhD, J. Michael McWilliams, MD, PhD, and colleagues; the researchers compared a group invited to participate in the program with a control group that did not receive an invitation.

The results of the study were encouraging, demonstrating a substantial increase in inhaler adherence among individuals who enrolled in the program. While the program did not significantly impact the rate of COPD exacerbations or overall healthcare spending, it did highlight a positive effect on inhaler usage, particularly among Black patients.

These findings underscore the necessity of a comprehensive approach to COPD management that addresses both financial and educational factors. By providing accessible, affordable inhalers and coupling them with targeted support, healthcare providers can significantly improve patient outcomes and reduce the overall burden of COPD.